537
Views
23
CrossRef citations to date
0
Altmetric
Reviews

Emerging drugs for functional dyspepsia

, MD PhD &
Pages 283-292 | Published online: 17 Mar 2011
 

Abstract

Introduction: Functional dyspepsia (FD) is a highly prevalent condition with a major impact on quality of life and high socio-economic and healthcare costs. To date, no treatment of established efficacy in FD is available.

Areas covered: This review of the literature summarizes recent progress in drug development for FD. Gastroprokinetics are considered therapeutically relevant in FD, although it has been difficult to prove symptomatic benefit. Recently studied drugs include 5-HT4 receptor agonists (tegaserod), motilin receptor agonists (GSK962040 and others) and ghrelin receptor agonists (TZP-101, TZP-102). Fundic relaxant drugs are a novel approach to FD therapy. Recently studied drugs include 5-HT1A receptor agonists (buspirone, tandospirone, R137696) and acotiamide (or Z-338 or YM443), a first-in-class muscarinic M1/M2 receptor antagonist and cholinesterase inhibitor. Extensive Phase II studies support the potential efficacy of acotiamide, especially for postprandial distress syndrome. In refractory cases, psychotropics are considered and recently studied agents include venlafaxine, which in a large multi-center study did not confirm efficacy, and a combination preparation of flupenthixol/melitracen, which showed potential efficacy in a small study.

Expert opinion: While many new prokinetic drugs are in the early stages of evaluation, acotiamide emerges as the drug with a promising efficacy profile. Convincing evidence for the efficacy of psychotropics is lacking.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.